Home>Topics>Stocks>InterMune

InterMune ITMN

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gilead Most Likely Suitor

      Headlines

      Thu, 11 Sep 2014

      By Dr. Paul Nunzio DeSantis, Pharm.D : Abbvie's (NYSE: ABBV )'s proactive and strategic efforts throughout 2014 are undoubtedly welcome measures by shareholders who are increasingly weary of ABBV's dependence on Humira as patent expiration arrives in 2016. We specifically support their £53.80 bid

    2. Is Roche At Risk Of Losing Its Way?

      Headlines

      Tue, 9 Sep 2014

      By Stephen Simpson, CFA : By just about any reasonable standard, Roche (OTCQX: RHHBY ) is an exceptional pharmaceutical and diagnostics company. Through internal efforts and acquisitions large and small (particularly Genentech), Roche has become one of the largest players in oncology, with ...

    3. Buying Biotech

      Headlines

      Wed, 3 Sep 2014

      Idenix (NASDAQ: IDIX ) and Intermune (NASDAQ: ITMN ) . Why so many pharma deals ..... the same time, we learned that Intermune , a Brisbane, California-based ..... gobbled up by a larger rival. Intermune has been developing drugs to

    4. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      s GSK acquisition in 2012 of Human Genome Sciences and Roche's RHHBY recent announcement of its plans to acquire InterMune ITMN . Given Big Pharma's flush balance sheets, we expect more biotechs to be acquired by large pharmaceutical firms

    5. FBT First Trust NYSE Arca Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      GlaxoSmithKline's GSK acquisition in 2012 of Human Genome Sciences and Roche's recent announcement of its plans to acquire InterMune ITMN . Given Big Pharma's flush balance sheets, we expect more biotechs to be acquired by large pharmaceutical firms

    6. When Will M&A Come To The Hepatitis C Space?

      Headlines

      Thu, 28 Aug 2014

      click to enlarge) Yesterday, Roche acquired InterMune (NASDAQ: ITMN ) in an over $8 billion deal with an almost 40 ..... premium. The main attraction for Roche of acquiring InterMune is the company's drug for idiopathic pulmonary

    7. Fitch Affirms Roche at 'AA'/Stable on InterMune Buy

      Headlines

      Thu, 28 Aug 2014

      affirmed at 'F1+'. The Outlook is 'Stable'. A full list of rating actions is available at the end of this commentary. The rating affirmation follows Roche's proposed tender offer to acquire 100% of US-based biotech company InterMune

    8. Tekmira +4% on takeover rumors; Shire, Glaxo said to have interest

      Headlines

      Wed, 27 Aug 2014

      suggest interested parties could include Shire (NASDAQ: SHPG ) and GlaxoSmithKline (NYSE: GSK ); the report suggests the recent premium paid for InterMune could put a valuation of at least $40/share on TKMR. Post your comment!

    9. InterMune drug may offer big upside to Roche if aimed at liver

      Headlines

      Wed, 27 Aug 2014

      (Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

    10. With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune

      Headlines

      Tue, 26 Aug 2014

      leverage existing efforts in pulmonary/respiratory disease, Roche has stepped up with an expensive bid for InterMune (NASDAQ: ITMN ). Roche Finally Makes Its Move Even though Roche has been somewhat active on the M&A front (recently acquiring

    « Prev12345Next »
    Content Partners